Study Indicates That Detection of EGFR in Blood May Predict Iressa and Tarceva Response in NSCLC | GenomeWeb

Researchers from the National Cancer Research Center in Tokyo report in the current issue of Clinical Cancer Research that they have successfully used DxS' Amplified Refractory Mutation System technology to identify drug-sensitizing mutations in the epidermal growth factor receptor gene from DNA floating free in serum, a step that may foreshadow the use of molecular diagnostics to monitor patients' likely drug responses in non-small cell lung cancer, and by extension other cancers.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Pacific Biosciences is hosting a competition in which researchers are vying to win free sequencing for an organism with the most interesting genome.

An opinion piece appearing in Newsday likens familial DNA searches to stop-and-frisk policies.

The San people of Africa have drawn up a code of conduct for researchers, according to the Conversation.

In Nature this week: genotypes linked to hip osteoarthritis, and more.